Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.

Aurobindo Pharma Limited

Solbosch provides a variety of medical and paramedical specialties. It is equipped with a viral air purifier.

Solbosch

Intas Pharmaceuticals Ltd. is involved in the development, manufacturing, and marketing of pharmaceutical formulations, including a wide range of products from tablets to injectables to newer drugs globally. Self-described as a leading multinational company, Intas operates in over 85 countries.

Intas Pharmaceuticals Ltd.

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Marksans Pharma Limited

Aurobindo Pharma is a fully integrated pharmaceutical company that manufactures and sells a wide range of products globally, with specific focus on active pharmaceutical ingredients and formulations. The company exports to over 150 countries, with a major share of its revenue from international operations.

Metric
Company Name	Aurobindo Pharma Limited	Solbosch	Intas Pharmaceuticals Ltd.	Marksans Pharma Limited
Symbol	AUROPHARMA			MARKSANS
MSH ID	COM:AUROBINDO	BE:SOLBOSCH	COM:INTASPHARMA	COM:MARKSANSPHARMA
Market	STOCKS	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Drug Manufacturers - Specialty & Generic	Healthcare	Pharmaceuticals	Drug Manufacturers - General
Country	IN	BE	IN	IN
Stage
Employee Count	23.45K			852
Website	aurobindo.com	solbosch.be	intaspharma.com	marksanspharma.com
LinkedIn		le-solbosch
Founders

Metric
Market Cap	9.12B	1.03B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	3.42B	257.07M
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.29B	91.07M
EBITDA	689.83M	54.14M
Operating Income	510.18M	45.37M
Net Income	374.60M	37.04M
EPS	0.64	0.08
Diluted EPS	0.64	0.08
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.55	0.52
Operating Profit Margin	0.17	0.20
EBITDA Margin	0.20	0.21
Net Profit Margin	0.12	0.15
Return on Equity	0.14	0.24
Return on Assets	0.08	0.12
Return on Capital Employed	0.15	0.19

COM:AUROBINDO

Aurobindo Pharma

Last Close

1,223.70

25/11 09:40

Market Cap

772.21B

Beta: -

Volume Today

1.13M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	25.84	22.85
P/B Ratio	2.13	3.61
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.11	6.36
EV Multiple	13.82	29.20

Metric
Days Sales Outstanding	63.94	82.40
Days Payables Outstanding	134.46	74.71
Days Inventory Outstanding	256.02	198.04
Operating Cycle	317.31	274.00
Cash Conversion Cycle	201.05	188.03
Asset Turnover	0.66	0.85

Metric
Operating Cash Flow	290.99M	30.24M
Free Cash Flow	-129.49M	5.58M
Cash Flow to Debt	0.47	0.55
Operating Cash Flow/Sales	0.11	0.06
Free Cash Flow Yield	-0.00

Metric
Cash & Equivalents	741.22M	79.52M
Accounts Receivable	-31.19M	-4.39M
Inventory	1.16B	72.96M
Goodwill	70.26M	4.66M
Debt to Capitalization	0.18	0.11
Debt to Assets	0.15	0.05
Current Ratio	1.81	5.12
Quick Ratio	1.18	3.19

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	-0.00
R&D to Revenue
SG&A to Revenue